Skip to main content
. 2023 Jan 9;7(11):2436–2448. doi: 10.1182/bloodadvances.2022008981

Figure 3.

Figure 3.

Patients with previous allo-HSCT according to time from HSCT to relapse. Event-free survival (A), overall survival (B) with estimates for 24 months after CAR T-cell infusion, relapse-free survival (C), CIR (D), NRM (E), and duration of B-cell aplasia (F) with estimates for 24 months after response.